API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.
Lead Product(s): Birinapant,IGM-8444
Therapeutic Area: Oncology Product Name: TL32711
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: IGM Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells.
Lead Product(s): Birinapant,IGM-8444
Therapeutic Area: Oncology Product Name: TL32711
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: IGM Biosciences
Deal Size: $352.5 million Upfront Cash: $1.0 million
Deal Type: Licensing Agreement January 11, 2021
Details:
The original agreement between Medivir and TetraLogic included milestone payments with predetermined amounts as well as royalty obligations to TetraLogic if and when Medivir develops, markets or out-licenses birinapant further.
Lead Product(s): Birinapant
Therapeutic Area: Oncology Product Name: TL32711
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medivir
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 11, 2020